2022 World Conference on Lung Cancer (ePosters)-EP08.02-013. Prognostic Utility of the ALI (Advanced Lung Index) in Crizotinib-Treated ALK and ROS1Fusion-Positive NSCLC

EP08.02-013. Prognostic Utility of the ALI (Advanced Lung Index) in Crizotinib-Treated ALK and ROS1Fusion-Positive NSCLC

Back to course

Pdf Summary

A study was conducted to determine the prognostic utility of the Advanced Lung Index (ALI) in patients with ALK and ROS1 fusion-positive non-small cell lung cancer (NSCLC) who were treated with crizotinib. The ALI is a blood-based marker associated with systemic inflammation and is used to assess the tumor microenvironment. The study found that patients with a high ALI score, indicating low systemic inflammation, had superior overall survival compared to those with a low ALI score, indicating high systemic inflammation. It was also observed that patients with a low ALI score had a higher rate of non-response to crizotinib, limiting the effectiveness of targeted therapy. Brain metastases were more common in patients with a low ALI score. The study suggests that ALI scores may be helpful in identifying patients at risk of non-response to crizotinib and may complement subjective assessments of patient performance status. ALI scores were found to be predictive of the clinical response to crizotinib and were associated with patient outcomes. The study concludes that ALI scores are an inexpensive and accessible tool that can aid in the treatment decision-making process for patients with ALK and ROS1 fusion-positive NSCLC. Factors such as ECOG (Eastern Cooperative Oncology Group) performance status and the presence of brain metastases were also found to be prognostic of patient outcomes and response to crizotinib, but ALI scores had a greater ability to differentiate response to crizotinib.

Asset Subtitle

Amanda Gibson

Meta Tag

Speaker Amanda Gibson

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

Advanced Lung Index

ALI

prognostic utility

ALK fusion-positive NSCLC

ROS1 fusion-positive NSCLC

crizotinib

systemic inflammation

tumor microenvironment

overall survival

non-response to crizotinib